Establishment of a CYP2C19 genotyping assay for clinical use

American Journal of Clinical Pathology

Volumn 139, Issue 2, 2013, Pages 202-207

  Cervinski, Mark A ^a   Schwab, Mary C ^a   Lefferts, Joel A ^a   Lewis, Lionel D ^b   Lebel, Kimberly A ^c   Tyropolis, Allison M ^c   Pflueger, Solveig M V ^c   Tsongalis, Gregory J ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c Baystate Health ^*  (United States)

Author keywords

Clopidogrel; CYP2C19; TaqMan

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; EDETIC ACID; GENOMIC DNA; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; DNA; DRUG DERIVATIVE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ALLELE; BLOOD SAMPLING; ENZYME ACTIVITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ACUTE CORONARY SYNDROME; ARTICLE; BLOOD; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; GENOTYPING TECHNIQUE; HUMAN GENOME; METHODOLOGY; VALIDATION STUDY;

ACUTE CORONARY SYNDROME; ARYL HYDROCARBON HYDROXYLASES; DNA; GENOME, HUMAN; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; TICLOPIDINE;

MLCS; MLOWN;

EID: 84875082712     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP9K2KDOCPCBSV     Document Type: Review

References (24)

1. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. The human cytochrome P450 (CYP) allele nomenclature database. Available at http://www.cypalleles. ki.se/
2. Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos. 2002;30:1288-1295.
3. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;84:891-896.
4. Ma TK, Lam YY, Tan VP, et al. Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel. Pharmacol Ther. 2010;125:249-259.
5. Geisler T, Schaeffeler E, Dippon J, et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics. 2008;9:1251-1259.
6. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-375.
7. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849-857.
8. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5:2429-2436.
9. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-362.
10. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121:512-518.
11. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79:103-113.
12. Scott SA, Sangkuhl K, Gardner EE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011;90:328-332.
13. Martis S, Peter I, Hulot JS, et al. Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes [published online April 10, 2012]. Pharmacogenomics J. doi: 10.1038/tpj.2012.10.
14. Harmsze AM, van Werkum JW, Hackeng CM, et al. The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet Genomics. 2012;22:169-175.
15. Food and Drug Administration (FDA). FDA drug safety communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Available at http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm
16. Pratt VM, Zehnbauer B, Wilson JA, et al. Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: A GeT-RM and Association for Molecular Pathology collaborative project. J Mol Diagn. 2010;12:835-846.
17. Pettersen AA, Arnesen H, Opstad TB, et al. The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel. Thromb J. 2011;9:4.
18. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet. 2009;373:309-317.
19. Spartan. Spartan RX. Available at http://www.spartanbio. com/products/spartan-rx/
20. Roberts JD, Wells GA, Le May MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): A prospective, randomised, proof-of-concept trial. Lancet. 2012;379:1705-1711.
21. Langley MR, Booker JK, Evans JP, et al. Validation of clinical testing for warfarin sensitivity: Comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. J Mol Diagn. 2009;11:216-225.
22. Lee CC, McMillin GA, Babic N, et al. Evaluation of a CYP2C19 genotype panel on the GenMark eSensor® platform and the comparison to the Autogenomics Infiniti□ and Luminex CYP2C19 panels. Clin Chim Acta. 2011;412:1133-1137.
23. Wu AH, Babic N, Yeo K-T. Implementation of pharmacogenomics into the clinical practice of therapeutics: Issues for the clinician and the laboratory. Pers Med. 2009;6:315-327.
24. Andersson T, Flockhart DA, Goldstein DB, et al. Drugmetabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther. 2005;78:559-581.